British randomised controlled trial of AV and VV optimization ("BRAVO") study:rationale, design, and endpoints

Whinnett, Zachary I, Sohaib, S M Afzal, Jones, Siana, Kyriacou, Andreas, March, Katherine, Coady, Emma, Mayet, Jamil, Hughes, Alun D, Frenneaux, Michael and Francis, Darrel P and BRAVO Investigators (2014) British randomised controlled trial of AV and VV optimization ("BRAVO") study:rationale, design, and endpoints. BMC Cardiovascular Disorders, 14.

Preview

PDF (Published_Version) - Published Version Available under License Creative Commons Attribution. Download (859kB) | Preview

Abstract

Background Echocardiographic optimization of pacemaker settings is the current standard of care for patients treated with cardiac resynchronization therapy. However, the process requires considerable time of expert staff. The BRAVO study is a non-inferiority trial comparing echocardiographic optimization of atrioventricular (AV) and interventricular (VV) delay with an alternative method using non-invasive blood pressure monitoring that can be automated to consume less staff resources. Methods/Design BRAVO is a multi-centre, randomized, cross-over, non-inferiority trial of 400 patients with a previously implanted cardiac resynchronization device. Patients are randomly allocated to six months in each arm. In the echocardiographic arm, AV delay is optimized using the iterative method and VV delay by maximizing LVOT VTI. In the haemodynamic arm AV and VV delay are optimized using non-invasive blood pressure measured using finger photoplethysmography. At the end of each six month arm, patients undergo the primary outcome measure of objective exercise capacity, quantified as peak oxygen uptake (VO2) on a cardiopulmonary exercise test. Secondary outcome measures are echocardiographic measurement of left ventricular remodelling, quality of life score and N-terminal pro B-type Natriuretic Peptide (NT-pro BNP). The study is scheduled to complete recruitment in December 2013 and to complete follow up in December 2014. Discussion If exercise capacity is non-inferior with haemodynamic optimization compared with echocardiographic optimization, it would be proof of concept that haemodynamic optimization is an acceptable alternative which has the potential to be more easily implemented.

Item Type:	Article
Uncontrolled Keywords:	biological markers,blood pressure determination,cardiac resynchronization therapy,cardiac resynchronization therapy devices,clinical protocols,cross-over studies,echocardiography, doppler,exercise test,exercise tolerance,great britain,heart failure,hemodynamics,humans,natriuretic peptide, brain,peptide fragments,photoplethysmography,predictive value of tests,quality of life,questionnaires,recovery of function,research design,time factors,treatment outcome,ventricular function, left,ventricular remodeling
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Depositing User:	Pure Connector
Date Deposited:	09 Mar 2015 07:28
Last Modified:	23 Apr 2023 00:59
URI:	https://ueaeprints.uea.ac.uk/id/eprint/52413
DOI:	10.1186/1471-2261-14-42

Downloads

Actions (login required)

View Item